CEO ONAKids

Barcelona, Spain Call4Entrepreneurs - The Collider About the job CEO ONAKids (The Collider Programme) ONAkids | Early Screening for Language Development Disorders Are you seeking a new entrepreneurial adventure in health innovation with the opportunity to build a high-impact medtech spin-off? ONAkids , project developed at the Brainlab Cognitive Neuroscience Research Group (Universitat de Barcelona) with the support of Fundació Bosch i Gimpera, is looking for an entrepreneurial profile with strong business acumen and founder experience to join the team. As the Entrepreneur, you will be part of our venture-building journey, leading the business validation phase hand-in-hand with the scientific team. At the end of this process, if the business and the team are validated, the spin-off will be incorporatedand you will become the CEO & Co-Founder of a disruptive medical device company transforming neonatal health. About ONAkids Language delay affects 1 in 5 children and is associated with long-term difficulties in reading, attention, socialization and mental health. Early detection significantly improves outcomes but today, no neonatal screening tool reliably identifies this risk. ONAkids has developed an EEG-based medical device that records newborns brain responses to speech sounds and, through cloud-based AI models, provides 80% prediction accuracy for language-development riskenabling early intervention within the first months of life. The team vision is to position ONAkids as a universal newborn screening tool , comparable in simplicity and cost to current mandatory hearing tests. Main project achivements so far: Validated AI algorithms reaching 80% accuracy. A protected database of 600 neonatal EEG recordings, with longitudinal follow-up available for approximately 200 cases. A dedicated prototype device designed for neonatal clinical use. Consistent competitive funding since 2021, securing a total of 400,000 including MICINN, AGAUR, Biocat and CRAASH. The Entrepreneur will play a critical role in advancing ONAkids by bringing business leadership, regulatory awareness, and strategic execution to build a viable, clinically validated and scalable medical device company. Key challenges include: Defining the vision, financial model and business strategy for the future spin-off. Leading patient journey definition and selecting the beachhead market. Coordinating clinical validation , regulatory pathways (CE/MDR; FDA desirable ) and market access. Securing the first clinical pilots and early adopters. Leading the first fundraising rounds (public and private). Managing day-to-day operations and executing the commercial roadmap. The Offer Relevant equity as CEO and Co-Founder once the company is established. 6,000 stipend (3 monthly instalments of 2,000 each). Opportunity to access a participative loan of up to 50K to finance the first phases of the project. International exposure through The Collider ecosystem (4YFN, Mobile World Congress, corporate & investor networks). Access to a structured programme supported by mentors, specialists, healthcare experts, industry partners and investors. Coworking space in Barcelona (Tech Barcelona Pier 01). Backing from the Universitat de Barcelona , Fundació Bosch i Gimpera, and a highly respected scientific team. This opportunity is for you If: You are an entrepreneur with experience founding or co-founding healthtech/medtech/digital health startups. Passionate about science-based innovation , child health and preventative care. Skilled in strategy, leadership, fundraising, and market access. Familiar with medical device development: clinical validation, regulation (MDR/CE), industrialization, go-to-market Experienced in securing public grants and private investment. A resilient, hands-on leader capable of bridging science, clinical practice and business. Eligible to work in Spain (passport or visa required). Fluent in English andSpanish; Catalan is a plus. About the Programme Founded in 2017, The Collider has supported more than 200 scientific projects , created 23 deep-tech spin-offs , and manages a portfolio valued at 112M , with a 77% survival rate. #J-18808-Ljbffr